SlideShare una empresa de Scribd logo
1 de 61
USFDA Approval Process
For
Drug Products & Biological Product
[NDA Vs. BLA]
By:

•

Girish A. Swami, (M.Pharm, PGDIPR, PGDDRA)

•

Mob.: +91-9881492626

•

Email- pr.girish@gmail.com
Outline
•
•
•
•
•
•

Overview of USFDA Framework
Biological Products
How are Biologics different?
Therapeutic Biologicals - Examples
Biologics in CBER or CDER
Regulation for Drugs & Biologics
–
–
–
–
–
–

Comparison to drugs
Inspection Team
Overview & Review Process
NDA and BLA (Similarities and Differences)
NDA/BLA Dossier content
BLA Post-approval requirement
Overview of Regulatory Framework
- USFDA
Introduction:
• The FDA is part of the Health and Human
services Department of the US Government.
• The FDA’s authority is based upon various laws
and statutory documents.
• The Food and Drug Administration (FDA) has
responsibility for regulation of drugs and
Biological products which are manufactured and
/ or sold in the US.
Organizational Structure
The FDA divided into following main Divisions or Centers.

 Center for Drug Evaluation and Research (CDER)
 Center for Biological Evaluation and Research (CBER)
 Center for Devices and Radiological Health (CDRH)
 Center for Veterinary Medicine (CVM)
 Office of Regulatory Affairs (ORA)
 Center for Food Safety and Applied Nutrition (CFSAN)
 National Center for Toxicological Research (NCTR)
 Center for Tobacco Products (CTP)
Regulatory Submission
Center for Drug Evaluation and Research
(CDER)
The CDER is responsible for the
regulation of Chemically – derived and
most therapeutic Biological products,
both New Drugs and Generics.
Center for Biologics Evaluation and Research
(CBER)

The Mission of CBER is to protect and
enhance

public

health

through

the

regulation of certain therapeutic Biological
Products as well as Blood Products,
Vaccines, Tissue and Gene Therapy
Products.
Center for Devices and Radiological Health
(CDRH)

The

CDRH

regulation

of

is

responsible

Medical

for

Devices

Radiation Emitting products

the
and
Center for Veterinary Medicine
(CVM)

The

CVM

regulation

is
of

responsible
Animal

Medicinal Products

or

for

the

Veterinary
Office of Regulatory Affairs
(ORA)
The ORA is the lead office for all field activities of the FDA. The
duties and functions of ORA are divided between four main offices:
•

Resource Management

•

Regional Operation

•

Criminal Investigations

•

Enforcement.
ORA regions are the Pacific, Southwest, Central, Southeast and
Northeast regions of the US. Each region supports a number of local
FDA offices.
Office of Combination Products
(OCP)
The OCP is responsible for general oversight of the agency’s
regulation of combination products. The primary responsibilities for
regulating specific combination products remain in one of the
product centers – CDER, CBER, CDRH.

The OCP also oversees multi center reviews of combination
products,

ensures

consistent

and

appropriate

post-approval

regulation of combination products, and resolves disputes relating to
combination products.
Biological Product
(Biologic / Biologics / Biological)

Biological Product – a “Virus, Therapeutic
Serum, Toxin, Antitoxin, Vaccine, Blood, Blood
Component or Derivative, Allergenic product, or
Analogous product, applicable to the Prevention,
Treatment or Cure of a Disease or Condition of
human beings.”
- As per Section 351 PHS Act
Biologics vs. Drugs
Biologic products generally more complex
• Many innovative products.
– Virtually every new biologic is a novel product (NME)
• Demonstration of product comparability is more
difficult.
• Changes in manufacturing and scale-up can impede
(obstruct) overall approval process.
USFDA NDA Vs BLA
USFDA NDA Vs BLA
Biologics - Unique Aspects !
Source material for biologics
– Potential for transmission of adventitious agents
– Bacteria, mycoplasma, fungi, viruses, TSE agents
– Need for in-process controls, validation process validation

Heat Sensitive & susceptible to microbial contamination
– Controlled temperature during production
– Aseptic processing throughout
– Cannot terminally sterilize

Formulations
– Majority Parenteral
– Issues with concentration, Multi-use vials
Pharmacokinetics
– Not well established
– May not be able to measure

Potential Immunogenicity
– Desirable in vaccine strategies
– Unwanted effects in other settings (single or
chronic-dosing)
• Altered PK
• Allergic, serum-sickness reactions
• Cross reactivity to normal, essential protein

– Limitations of non-clinical studies
• Species-specific antibody development
Therapeutic Biologicals Examples
• Cytokines
– Interferons- α, β, γ
– Interleukins- IL2, IL11

• Hematopoietic growth factors
– Erythropoietins
– CSFs (Colony-stimulating factor)

• Enzymes
– Thrombolytics (e.g. streptokinase, TPA)
– Aldurazyme
Monoclonal Antibodies and related products
– Anti-EGFR (Cetuximab, Panitumumab)
– Anti-Alpha4 integrin (Natalizumab)

Fusion proteins
– TNFR linked to Fc portion of human IgG
(Etanercept)

Fab Fragments
– Anti-VEGF (Ranibizumab)
– Anti-TNFα (certolizumab pegol)
Oncology
– Herceptin (trastuzumab) breast cancer, ushers in new area of
highly targeted therapy
– Rituxan (rituximab) targets some lymphomas
– Zevalin (ibritumomab tiuxetan), monoclonal antibody targeted
radiotherapy
– Campath (alemtuzumab) for CML (Chronic Myeloid Leukaemia)
– Avastin (Bavacuzimab Bavacuzimab) first line metastatic
colorectal Cancer
CBER or CDER
An applicant must determine which division of
the FDA to submit its application, as the Center
for Biologics Evaluation and Research (CBER)
and the Center for Drug Evaluation and
Research (CDER) share responsibility for BLAs.
Products Regulates by CBER
•

Allergenics
Patch tests used to diagnose the causes of contact dermatitis. Extracts used to diagnose and treat rhinitis
("hay fever"), allergic sinusitis and conjunctivitis, and bee stings.

•

Blood
Blood and blood components used for transfusion, such as red blood cells, plasma, and platelets.e.g
Immunoglobuilns.

•

Devices
Medical devices and tests used to safeguard blood, blood components, and cellular products from HIV,
hepatitis, syphilis, and other infectious agents. Machines and related software used to collect blood and
blood components.

•

Gene Therapy
Gene therapy products that replace a person's faulty or missing genetic material.

•

Human Tissues and Cellular Products
Human tissues for transplantation, such as skin, tendons, ligaments, and cartilage. Cellular products, such
as human stem cells and pancreatic islets.

•

Vaccines
Vaccines used for the prevention of infectious diseases, such as mumps, measles, chicken pox,
diphtheria, tetanus, influenza, hepatitis, smallpox, and anthrax.

•

Xenotransplantation Products
Xenotransplantation products use nonhuman tissues or organs into human recipients to treat human
diseases such as liver failure, where human materials are not always available.
Products Regulates by CDER
Therapeutic Biological Products Transferred to CDER
•

Monoclonal antibodies for in vivo use.

•

Proteins intended for therapeutic use, including cytokines (e.g. interferons),
enzymes (e.g. thrombolytics), and other novel proteins, This category includes
therapeutic proteins derived from plants, animals, or microorganisms, and
recombinant versions of these products.

•

Immunomodulators (non-vaccine and non-allergenic products intended to treat
disease by inhibiting or modifying a pre-existing immune response).

•

Growth factors, cytokines, and monoclonal antibodies intended to mobilize,
stimulate, decrease or otherwise alter the production of hematopoietic cells in
vivo.
About Combination Products
Combination products are therapeutic and diagnostic products that
combine drugs, devices, and/or biological products. Combination
products involve components that would normally be regulated
under different types of regulatory authorities, and frequently by
different FDA Centers like CBER, CDER & CDRH.
(i.e.,Drug/Device, Biologic/Device, Drug/Biologic, or Drug/Device/Biologic)
Examples:
– Orthopedic implant with growth factors,
– Prefilled syringes
– Metered dose inhalers
– Transdermal patches
– Catheter with antimicrobial coating
Regulation for Drugs &
Biologics
Product Type
FD & C Act
PHS Act
Component Jurisdiction
Generic Equivalence
Establishment Standards
21 CFR Part 211
21 CFR Part 312
21 CFR 600
21 CFR 314

Drugs
Biological
Products Products
√
√
√
√
√
√
√
√
√
√
√
√
√
Law or Act.
Drug Products fall under the Food, Drug
and Cosmetic Act.
While
Biological Products fall under the Food,
Drug and Cosmetic act,
& Public
Health Service Act.
Generic Equivalence
Generics : Abbreviated New Drug Application (ANDA)
A generic drug product is one that is comparable to an innovator
drug product in Dosage form, Strength, Route of administration,
Quality, Performance characteristics and Intended Use.
While
Follow-on Biologic or Biosimilar
A follow-on biologic is similar but not identical to the brandname, or
innovator, product made by the pharmaceutical or biotechnology
industry; biosimilar is the term used in the European Union.
Establishment Standards
General Information –
(i) Product, personnel, equipment, waste and air flow
(ii) Illustration or indication of which areas are served by each air handling unit
(iii) Air pressure differentials between adjacent areas.
Water System –
(i) General description of W/S
(ii) Validation summary
(iii) Routine w/s monitoring program.

HVAC System – (Heating, Ventilation and Air Conditioning Systems),
(i) General description
(ii) Validation summary
(iii) Routine monitoring program.
Computer Systems – The application should contain information on computer
systems which control critical manufacturing processes.
Contamination/Cross Contamination Issues – The application should contain the
following information regarding methods to prevent contamination and cross
contamination to supplement information requested in the CMC
(i) Cleaning procedures and validation
(ii) Containment features.
USFDA Pharmaceutical Team
(Inspectorate)
FDA’s

Pharmaceutical

Inspectorate

was

established under the agency’s Pharmaceutical
cGMP’s for the 21st century: A Risk-Based
Approach and Reporting to CDER
USFDA Biologics Team
The FDA team biologics was established in 1997
to assure the quality and safety of Biological
Products.
It consists of a core team of,
1.

Certified ORA investigators,

2.

CBER certified inspectors, and

3.

Specially trained compliance officers representing both ORA and
CBER
Overview & Review
of
NDA & BLA
USFDA NDA Vs BLA
NDA & BLA
(Similarities and Differences)
NDA and BLA - Similarities

There are many similarities
– Regulations
– Guidance documents
– PDUFA
NDA and BLA - Similarities
Specific Similarities Include
• IND regulations, Fast Track designation, Special
Protocol Assessment (SPA)
• Financial Disclosure, CTD format
• Labeling and Advertising (21CFR 201-202)
• Pediatric study requirements and waivers
• Accelerated Approval
• Orphan Exclusivity
Most differences are due to
Type of Product
Not due to which
FDA Center Regulates The Product
Unique to NDAs
• Patent Exclusivity (Generics, 505b2, & Orange Book)
• Pediatric Exclusivity (written requests)
• NDA Field Copies
• Regulations more detailed (NDA content; Filing criteria etc.)
Unique to BLAs
U.S. License
• Product and facility must meet “Product standards” prior to license issuance
• Review includes
–
–
–
–

•

Application review
Facility inspection (Pre-approval, review members participate)
Method validation (complete)
Compliance check

Cooperative manufacturing arrangements permitted
– Divided, Shared, Contract

FDA “official” release (21 CFR 610.2) of each product lot
(at discretion of FDA)
Container & Pkg. Label Requirements
Specific information will be required depending on the type of BLA
(e.g., Blood, Vaccines).
NDA & BLA Application
NDA and BLA are applications to market a new
product. NDAs are used by CDER (center for
drugs) and BLAs are used by CBER (center for
biologics)
– The BLA requires close scrutiny of the
and facilities, because of the greater
products.

manufacturing process
variability of biological

– The application will include complete reports on all studies
including patient listings, analysis according to the original
statistical analysis protocol (SAP) as well as any exploratory
analysis.
– Although there is no regulatory mechanism in the U.S. to approve a
generic version of a product that is marketed under a BLA, it is
possible that a generic version of a biotech product that has been
approved under an NDA could be approved.
– This confusing situation results because some biotech products are
approved under NDAs while others are approved under BLAs.
– Review and approval of an NDA or BLA are based on the
demonstration of safety and efficacy assessed from detailed reports
of the clinical trials; particularly randomized controlled studies.
– Biological products are a subset of drugs; therefore both are
regulated under provisions of the FDC Act. However, only
biological products are licensed under section 351 of the PHS Act.
(As previously noted, some therapeutic protein products are
approved under section 505 of the FDC Act, not under the PHS
Act.)
– Among other things, safety and purity assessments must consider
the storage and testing of cell substrates that are often used to
manufacture biologics. A potency assay is required due to the
complexity and heterogeneity of biologics.
Law

Regulation (21 CFR)

IND

FD & C Act

25, 50, 211, 312

BLA

FD & C Act. &
PHS Act.

25, 201-2, 207, 211, 600

NDA

FD & C Act.

25, 201-2, 207, 211, 314

Post BLA

FD & C Act. &
PHS Act.

201-2, 211, 600

FD & C Act.

PDUFA

25, 201-2, 207, 211, 314

POST NDA

________
Same

Same

Where,

CFR
– Code of Federal Regulations
PDUFA – Prescription Drug User Fee Act.
IND
– Investigational New Drug Application
BLA
– Biologics License Applications
NDA
– New Drug Application
PART 25 Environmental Impact Considerations
PART 50 Protection of Human Subjects
PART 201 Labeling
PART 211 Current Good Manufacturing Practice for Finished Pharmaceuticals
PART 312 Investigational New Drug Application
PART 207 Registration of producers of Drugs and listing of Drugs in Commercial Distribution
PART 600 Biological Products: General
PART 314 Applications for FDA approval to market a New Drug
21 CFR PART 600
BIOLOGICAL PRODUCTS: GENERAL
Licensed biological products regulated by the Center
for Biologics Evaluation and Research (CBER)
Examples of such submissions include: Biologics
license applications (BLAs) and their amendments and
supplements, adverse experience reports, biological
product deviation reports, fatality reports, and other
correspondence.
21 CFR Part 600
BIOLOGICAL PRODUCTS: GENERAL
•

Subpart A: Definitions

•

Subpart B: Establishment Standards
– Personnel
– Facility, equipment, animals
– Retention samples
– Biological Product Deviations

•

Subpart C: Establishment Inspections

•

Subpart D: Reporting of Adverse Events
– Postmarketing reporting
– Distribution reports
21 CFR Part 610
GENERAL BIOLOGICAL : PRODUCT STANDARDS
•

Release
– 610.1– lot release (manufacturer)
– 610.2– Samples for “Official” FDA testing and release

•

Testing
–
–
–
–
–

Potency
General Safety
Sterility
Purity (including moisture)
Mycoplasma

•

Dating Periods

•

Labeling
21 CFR PART 314
Applications for FDA approval to market a New Drug
Scope of this part.
(a) This part sets forth procedures and requirements for the submission
to, and the review by, the Food and Drug Administration of
applications and abbreviated applications to market a new drug
under section 505 of the Federal Food, Drug, and Cosmetic Act, as
well as amendments, supplements, and postmarketing reports to
them.
(b) This part does not apply to drug products subject to licensing by
FDA under the Public Health Service Act (58 Stat. 632 as amended
(42 U.S.C. 201et seq. ) and subchapter F of chapter I of title 21 of
the Code of Federal Regulations.

Ref: 50 FR 7493, Feb. 22, 1985, as amended at 57 FR 17981, Apr. 28, 1992; 64 FR 401, Jan. 5, 1999
Current Laws
Public Health Service Act (1944)
– Section 351 - Licensure of biological establishments
and products.

FFD&C Act (1938, 1962)
– Interprets that “biological products” are also “drugs”
– The FFD&C Act. applies to a biological product,
except no application required under section 505.
PHS Act
The Secretary shall approve a biologics license application:
– On the basis of a demonstration that
• Product is safe, pure and potent
• The facility (ies) meet standards designed to assure that it
continues to be safe, pure, and potent
– If the applicant consents to the inspection of the facility(ies)
– Each package of biological product must bear the U.S. license
number
Product Standards
CFR Standards for Biologics include:
(p) “Safety” means the relative freedom from harmful effect to persons
affected, directly or indirectly, by a product when prudently administered,
taking into consideration the character of the product in relation to the
condition of the recipient at the time.
(r) “Purity” means relative freedom from extraneous matter in the finished
product, whether or not harmful to the recipient or deleterious to the
product. Purity includes but is not limited to relative freedom from residual
moisture or other volatile substances and pyrogenic substances.
(s) “Potency” is interpreted to mean the specific ability or capacity of the
product, as indicated by appropriate laboratory tests or by adequately
controlled clinical data obtained through the administration of the product in
the manner intended, to effect a given result.
- 21 CFR 600.3 and Part 610
‘Approval Letter’
“This letter hereby issues Department of Health and Human
Services U.S. License No. XXXX to ___________ in accordance
with the provisions of Section 351(a) of the Public Health
Service

Act

controlling

the

manufacture

and

sale

of

biological products. This license authorizes you to introduce
or deliver for introduction into interstate commerce, those
products for which your company has demonstrated compliance
with establishment and product standards.”
BLA / NDA
Dossier Content
•
•
•
•
•
•
•
•

A copy of the cover letter attached to the archival copy
A completed application Form FDA 356h
A copy of the summary
A copy of the general index of the entire application
A letters of reference or authorization, if appropriate
Patent Information
Manufacturer Information
Product/Manufacturing Information (CMC)
–
–
–
–
–
–

•
•
•

Source material / raw material
Manufacturing process and controls
Formulation
Facility information
Contamination / cross-contamination information
Environment assessment or categorical exclusion

Pre-clinical Studies
Clinical Studies
Labeling
Application Forms
FDA 356h – Application to Market a New or Abbreviated new drug or biologic
for Human Use

FDA-3356 – Establishment Registration and listing for Human cells, Tissues,
And Cellular and Tissue based products (HCT/Ps)

FDA-3486 – Biological Product deviation report

Vaers form – Vaccine Adverse Event Reporting System
Patent Information
An applicant must submit information on each patent that
claims the drug or a method of using the drug that is the
subject of the BLA and with respect to which a claim of
patent infringement could reasonably be asserted.
An applicant must submit basic information about each patent,
including the following:
(i) Patent number and the date on which the patent will expire;
(ii) Type of patent;
(iii) Name of patent owner;
(iv) If the patent owner or applicant does not reside or have a place
of business within the U.S., the name of the agent of the patent
owner or applicant who resides or maintains a place of business
within the U.S. authorized to receive notice of patent certification.
Labeling
Label should include:
(i) The proper name of the product;
(ii) The name, address and license number of the manufacturer;
(iii) The US License number must appear on the product labeling.
(iv) The expiration date;
(v) The recommended individual dose, for multiple dose containers;
(vi) The statement “Rx only” for prescription Biologicals; and
(vii) Minimum potency of product expressed in terms of official
standard of potency or, if potency is a factor and no U.S.
standard of potency has been prescribed, the word “No U.S.
standard of potency”
Biologic License Application
(BLA)
Under the Public Health Services Act, the Federal Food and Drug
Administration (FDA) has been given the authority, concurrent with
its authority under the Food Drug and Cosmetic Act, to regulate
biologics. The FDA regulates a wide range of biologics, including,
but not limited to, vaccines, blood and blood by-products, certain
monoclonal antibodies, tissue and cellular products.
Within the FDA, the Center for Biologics, as well as the Center for
Drug Evaluation and Research, can be responsible for the
regulation of biologics.
– Biologics are evaluated for market by the FDA through the filing of a
Biologic License Application (BLA).
– A BLA, although similar to a New Drug Application (NDA), has its own
set of intricate requirements.
– Applicant has to provided the information in an acceptable format,
under the applicable regulations. However, applicants must be
cognizant that unique and specific information will be required
depending on the type of BLA (e.g., blood, vaccines).
Archival and Review Copies of
BLA
Federal regulations require the submission of two
copies of a BLA – Archival and Review.
Archival Copy
The archival copy is a complete copy of an application
submission and must be bound in a BLUE cover jacket.
The archival copy should include a cover letter to:
(i) confirm any agreements or understandings between the FDA and the
applicant;
(ii) identify a contact person regarding the application;
(iii) identify the reviewing division of the FDA and the HFD number; and
(iv) convey any other important information about the application.
Review Copy
The review copy is divided into six technical sections (“review
sections”) and should be submitted with each review section
separately bound in a specific color:
(i) Chemistry, Manufacturing and Controls (CMC) – RED;
(ii) Nonclinical Pharmacology and Toxicology – YELLOW;
(iii) Human Pharmacokinetics and Bioavailability – ORANGE;
(iv) Microbiology (if required) – WHITE;
(v) Clinical Data – LIGHT BROWN;
(vi) Statistical – GREEN.
eCTD format starting no later than two years after the
publication of the final guidance in the Federal Register,
and final guidance is likely to enforce in mid-to-late 2015
BLA
Post-Approval Requirements
• Required Annual Reports:
– Post Marketing Commitment (PMC) status (601.70)

• Other required submissions:
– Adverse Events (600.80)
– Distribution summary (600.81)
– Biologic Deviation Reports (600.14)
– Advertising and Promotional Labeling

• Periodic cGMP inspections
Changes to be Reported
(21CFR 601.12)
Manufacturing Changes
– Pre- Approval Supplements (PAS)
– 30 day Supplements (CBE30)
– Annual Reports - only if reportable changes
Labeling Changes
– Pre Approval Supplements
– Changes Being Effected (CBE) Supplements
– Annual Reports - only if reportable changes
Thank You
------ O -----GIRISH A. SWAMI
Asst. Manager – DRA & DQA

Serum Institute of India Ltd.

Más contenido relacionado

La actualidad más candente

US FDA Regulatory Submissions
US FDA Regulatory SubmissionsUS FDA Regulatory Submissions
US FDA Regulatory SubmissionsChandra Mohan
 
Plasma master file
Plasma master filePlasma master file
Plasma master fileSridhar S
 
Marketing authorization procedures in eu
Marketing authorization procedures in euMarketing authorization procedures in eu
Marketing authorization procedures in euRajaniKarpur
 
Marketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionDoninder Hooda
 
Dossier Preparation/ CTD (Common Technical Document)
Dossier Preparation/ CTD (Common Technical Document)Dossier Preparation/ CTD (Common Technical Document)
Dossier Preparation/ CTD (Common Technical Document)Prakash Ghimire
 
Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...
Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...
Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...Swapnil Fernandes
 
FDA Warning letter
FDA Warning letterFDA Warning letter
FDA Warning letterSridhar S
 
Dossier preparation and submission
Dossier preparation and submissionDossier preparation and submission
Dossier preparation and submissionDoninder Hooda
 
medical device regulatory approval in USA
medical device regulatory approval in USAmedical device regulatory approval in USA
medical device regulatory approval in USASuraj Pamadi
 
Fda med watch
Fda med watchFda med watch
Fda med watchSridhar S
 
Marketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureMarketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureOffice of Health Economics
 
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESREGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESVikas Rathee
 
Labeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Labeling/Advertising and Promotion, Import/Export, and Enforcement ActionsLabeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Labeling/Advertising and Promotion, Import/Export, and Enforcement ActionsMichael Swit
 
Regulation of medical device in japan
Regulation of medical device in japanRegulation of medical device in japan
Regulation of medical device in japanKrushnaAgnihotri
 
Regulatory aspects of Biologics in India
Regulatory aspects of Biologics in India Regulatory aspects of Biologics in India
Regulatory aspects of Biologics in India RichaTrivedi16
 
QUALITY SYSTEM REQUIREMENTS FOR NATIONAL GMP INSPECTORATES
QUALITY SYSTEM REQUIREMENTS FOR NATIONAL GMP INSPECTORATESQUALITY SYSTEM REQUIREMENTS FOR NATIONAL GMP INSPECTORATES
QUALITY SYSTEM REQUIREMENTS FOR NATIONAL GMP INSPECTORATESvasanthi chodavarapu
 
Investigational new drug application
Investigational new drug applicationInvestigational new drug application
Investigational new drug applicationGaurav Kr
 

La actualidad más candente (20)

GHTF Group 1
GHTF  Group 1GHTF  Group 1
GHTF Group 1
 
US FDA Regulatory Submissions
US FDA Regulatory SubmissionsUS FDA Regulatory Submissions
US FDA Regulatory Submissions
 
GHTF
GHTFGHTF
GHTF
 
Plasma master file
Plasma master filePlasma master file
Plasma master file
 
Marketing authorization procedures in eu
Marketing authorization procedures in euMarketing authorization procedures in eu
Marketing authorization procedures in eu
 
Marketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European Union
 
Dossier Preparation/ CTD (Common Technical Document)
Dossier Preparation/ CTD (Common Technical Document)Dossier Preparation/ CTD (Common Technical Document)
Dossier Preparation/ CTD (Common Technical Document)
 
Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...
Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...
Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...
 
FDA Warning letter
FDA Warning letterFDA Warning letter
FDA Warning letter
 
Dossier preparation and submission
Dossier preparation and submissionDossier preparation and submission
Dossier preparation and submission
 
medical device regulatory approval in USA
medical device regulatory approval in USAmedical device regulatory approval in USA
medical device regulatory approval in USA
 
Fda med watch
Fda med watchFda med watch
Fda med watch
 
Marketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureMarketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised Procedure
 
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESREGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
 
Labeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Labeling/Advertising and Promotion, Import/Export, and Enforcement ActionsLabeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Labeling/Advertising and Promotion, Import/Export, and Enforcement Actions
 
Regulation of medical device in japan
Regulation of medical device in japanRegulation of medical device in japan
Regulation of medical device in japan
 
Regulatory aspects of Biologics in India
Regulatory aspects of Biologics in India Regulatory aspects of Biologics in India
Regulatory aspects of Biologics in India
 
QUALITY SYSTEM REQUIREMENTS FOR NATIONAL GMP INSPECTORATES
QUALITY SYSTEM REQUIREMENTS FOR NATIONAL GMP INSPECTORATESQUALITY SYSTEM REQUIREMENTS FOR NATIONAL GMP INSPECTORATES
QUALITY SYSTEM REQUIREMENTS FOR NATIONAL GMP INSPECTORATES
 
ACTD- ASEAN
ACTD- ASEANACTD- ASEAN
ACTD- ASEAN
 
Investigational new drug application
Investigational new drug applicationInvestigational new drug application
Investigational new drug application
 

Destacado

US and EU Submission – Comparative
US and EU Submission – ComparativeUS and EU Submission – Comparative
US and EU Submission – ComparativeGirish Swami
 
Inprocess as per usp ip bp tablets
Inprocess as per usp ip bp tabletsInprocess as per usp ip bp tablets
Inprocess as per usp ip bp tabletsDeepak Jain
 
Protein and peptide drug delivery seminar-97-2003-final2
Protein and peptide drug delivery seminar-97-2003-final2Protein and peptide drug delivery seminar-97-2003-final2
Protein and peptide drug delivery seminar-97-2003-final2Pravin Chinchole
 
Protein and peptide drug delivery system
Protein and peptide drug delivery systemProtein and peptide drug delivery system
Protein and peptide drug delivery systemSagar Savale
 
Protein and-peptide-drug-delivery-systems
Protein and-peptide-drug-delivery-systemsProtein and-peptide-drug-delivery-systems
Protein and-peptide-drug-delivery-systemsGaurav Kr
 
Nikhil nanoparticles and liposomes
Nikhil nanoparticles and liposomesNikhil nanoparticles and liposomes
Nikhil nanoparticles and liposomesNikhil Patil
 
Liposomes in drug delivery
Liposomes in drug deliveryLiposomes in drug delivery
Liposomes in drug deliveryAliElshafey
 
Liposomes- A Novel Drug Delivery System
Liposomes- A Novel Drug Delivery SystemLiposomes- A Novel Drug Delivery System
Liposomes- A Novel Drug Delivery SystemSnehal Dhobale
 
New drug application
New drug applicationNew drug application
New drug applicationVKEkbote
 
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)Vamsikrishna Reddy
 
Protein and peptide delivery system
Protein and peptide delivery systemProtein and peptide delivery system
Protein and peptide delivery systemYamini Shah
 

Destacado (20)

US and EU Submission – Comparative
US and EU Submission – ComparativeUS and EU Submission – Comparative
US and EU Submission – Comparative
 
Patents & market exclusivity
Patents & market exclusivityPatents & market exclusivity
Patents & market exclusivity
 
Electrophoresis
ElectrophoresisElectrophoresis
Electrophoresis
 
Inprocess as per usp ip bp tablets
Inprocess as per usp ip bp tabletsInprocess as per usp ip bp tablets
Inprocess as per usp ip bp tablets
 
Protein and peptide drug delivery seminar-97-2003-final2
Protein and peptide drug delivery seminar-97-2003-final2Protein and peptide drug delivery seminar-97-2003-final2
Protein and peptide drug delivery seminar-97-2003-final2
 
Protein and peptide drug delivery system
Protein and peptide drug delivery systemProtein and peptide drug delivery system
Protein and peptide drug delivery system
 
Protein and-peptide-drug-delivery-systems
Protein and-peptide-drug-delivery-systemsProtein and-peptide-drug-delivery-systems
Protein and-peptide-drug-delivery-systems
 
Liposomes
LiposomesLiposomes
Liposomes
 
Protein drug delivery systems2
Protein drug delivery systems2Protein drug delivery systems2
Protein drug delivery systems2
 
Liposomes
LiposomesLiposomes
Liposomes
 
Nikhil nanoparticles and liposomes
Nikhil nanoparticles and liposomesNikhil nanoparticles and liposomes
Nikhil nanoparticles and liposomes
 
Liposomes in drug delivery
Liposomes in drug deliveryLiposomes in drug delivery
Liposomes in drug delivery
 
Liposomes
Liposomes Liposomes
Liposomes
 
Protein
ProteinProtein
Protein
 
Liposomes- A Novel Drug Delivery System
Liposomes- A Novel Drug Delivery SystemLiposomes- A Novel Drug Delivery System
Liposomes- A Novel Drug Delivery System
 
New drug application
New drug applicationNew drug application
New drug application
 
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
 
Protein and peptide delivery system
Protein and peptide delivery systemProtein and peptide delivery system
Protein and peptide delivery system
 
liposomes
liposomes liposomes
liposomes
 
Protein and peptide d d s
Protein and peptide d d sProtein and peptide d d s
Protein and peptide d d s
 

Similar a USFDA NDA Vs BLA

FDA Presentation on Biologics
FDA Presentation on BiologicsFDA Presentation on Biologics
FDA Presentation on BiologicsRobert Puopolo
 
Module 3 requirements for Biologics (peptide/protein medicines)
Module 3 requirements for Biologics (peptide/protein medicines)Module 3 requirements for Biologics (peptide/protein medicines)
Module 3 requirements for Biologics (peptide/protein medicines)TGA Australia
 
Introduction in Pharmacology
Introduction in PharmacologyIntroduction in Pharmacology
Introduction in PharmacologyEneutron
 
Pharmacovigilance Bioproducts & Biosimilars.pptx
Pharmacovigilance Bioproducts & Biosimilars.pptxPharmacovigilance Bioproducts & Biosimilars.pptx
Pharmacovigilance Bioproducts & Biosimilars.pptxAlaa Fadhel Hassan Alwazni
 
Introduction to Pharm.ppt
Introduction to Pharm.pptIntroduction to Pharm.ppt
Introduction to Pharm.pptDascoKenya
 
Regulatory agencies
Regulatory agenciesRegulatory agencies
Regulatory agenciesUrmila Aswar
 
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...Mohamed Fazil M
 
Pengantar Kimia Medisinal.pptx
Pengantar Kimia Medisinal.pptxPengantar Kimia Medisinal.pptx
Pengantar Kimia Medisinal.pptxGungAri6
 
US - FDA Regulatory Agency Overview.
US - FDA Regulatory Agency Overview.US - FDA Regulatory Agency Overview.
US - FDA Regulatory Agency Overview.Venugopal N
 
Glossary of terms used in pharmacovigilance. FINAL.pdf
Glossary of terms used in pharmacovigilance. FINAL.pdfGlossary of terms used in pharmacovigilance. FINAL.pdf
Glossary of terms used in pharmacovigilance. FINAL.pdfAlfiaAnsari2
 
Organizaton chart of us fda.
Organizaton chart of us fda.Organizaton chart of us fda.
Organizaton chart of us fda.Rovil Goel
 
concept of biosimilars
concept of biosimilarsconcept of biosimilars
concept of biosimilarskkoberoi
 
Biosimilars.pdf
Biosimilars.pdfBiosimilars.pdf
Biosimilars.pdfRavi890348
 
The regulation of medicines in Australia
The regulation of medicines in AustraliaThe regulation of medicines in Australia
The regulation of medicines in AustraliaTGA Australia
 
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_finalPpt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_finalRajashri Survase Ojha
 
cmc [ chemistry manufacturing control ]
cmc [ chemistry manufacturing control ]cmc [ chemistry manufacturing control ]
cmc [ chemistry manufacturing control ]Akshay Patil
 

Similar a USFDA NDA Vs BLA (20)

FDA Presentation on Biologics
FDA Presentation on BiologicsFDA Presentation on Biologics
FDA Presentation on Biologics
 
Module 3 requirements for Biologics (peptide/protein medicines)
Module 3 requirements for Biologics (peptide/protein medicines)Module 3 requirements for Biologics (peptide/protein medicines)
Module 3 requirements for Biologics (peptide/protein medicines)
 
Introduction in Pharmacology
Introduction in PharmacologyIntroduction in Pharmacology
Introduction in Pharmacology
 
Drugs.pdf
Drugs.pdfDrugs.pdf
Drugs.pdf
 
Regulatory Requirement for the Product Approval of Biologics Ppt.pptx
Regulatory Requirement for the Product Approval of Biologics Ppt.pptxRegulatory Requirement for the Product Approval of Biologics Ppt.pptx
Regulatory Requirement for the Product Approval of Biologics Ppt.pptx
 
Pharmacovigilance Bioproducts & Biosimilars.pptx
Pharmacovigilance Bioproducts & Biosimilars.pptxPharmacovigilance Bioproducts & Biosimilars.pptx
Pharmacovigilance Bioproducts & Biosimilars.pptx
 
Introduction to Pharm.ppt
Introduction to Pharm.pptIntroduction to Pharm.ppt
Introduction to Pharm.ppt
 
Regulatory agencies
Regulatory agenciesRegulatory agencies
Regulatory agencies
 
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...
 
Biosimilars
BiosimilarsBiosimilars
Biosimilars
 
Pengantar Kimia Medisinal.pptx
Pengantar Kimia Medisinal.pptxPengantar Kimia Medisinal.pptx
Pengantar Kimia Medisinal.pptx
 
US - FDA Regulatory Agency Overview.
US - FDA Regulatory Agency Overview.US - FDA Regulatory Agency Overview.
US - FDA Regulatory Agency Overview.
 
Glossary of terms used in pharmacovigilance. FINAL.pdf
Glossary of terms used in pharmacovigilance. FINAL.pdfGlossary of terms used in pharmacovigilance. FINAL.pdf
Glossary of terms used in pharmacovigilance. FINAL.pdf
 
Organizaton chart of us fda.
Organizaton chart of us fda.Organizaton chart of us fda.
Organizaton chart of us fda.
 
concept of biosimilars
concept of biosimilarsconcept of biosimilars
concept of biosimilars
 
Biosimilars
BiosimilarsBiosimilars
Biosimilars
 
Biosimilars.pdf
Biosimilars.pdfBiosimilars.pdf
Biosimilars.pdf
 
The regulation of medicines in Australia
The regulation of medicines in AustraliaThe regulation of medicines in Australia
The regulation of medicines in Australia
 
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_finalPpt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
 
cmc [ chemistry manufacturing control ]
cmc [ chemistry manufacturing control ]cmc [ chemistry manufacturing control ]
cmc [ chemistry manufacturing control ]
 

Último

How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17Celine George
 
Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfMohonDas
 
How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17Celine George
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational PhilosophyShuvankar Madhu
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?TechSoup
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17Celine George
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxDr. Asif Anas
 
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxPISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxEduSkills OECD
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxKatherine Villaluna
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17Celine George
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxheathfieldcps1
 
Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationMJDuyan
 
The Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsThe Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsEugene Lysak
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfMohonDas
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.EnglishCEIPdeSigeiro
 
How to Solve Singleton Error in the Odoo 17
How to Solve Singleton Error in the  Odoo 17How to Solve Singleton Error in the  Odoo 17
How to Solve Singleton Error in the Odoo 17Celine George
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and stepobaje godwin sunday
 
M-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxM-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxDr. Santhosh Kumar. N
 

Último (20)

How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17
 
Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdf
 
How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational Philosophy
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptx
 
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxPISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
 
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdfPersonal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptx
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptx
 
Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive Education
 
The Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsThe Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George Wells
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdf
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.
 
How to Solve Singleton Error in the Odoo 17
How to Solve Singleton Error in the  Odoo 17How to Solve Singleton Error in the  Odoo 17
How to Solve Singleton Error in the Odoo 17
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and step
 
Finals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quizFinals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quiz
 
M-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxM-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptx
 

USFDA NDA Vs BLA

  • 1. USFDA Approval Process For Drug Products & Biological Product [NDA Vs. BLA] By: • Girish A. Swami, (M.Pharm, PGDIPR, PGDDRA) • Mob.: +91-9881492626 • Email- pr.girish@gmail.com
  • 2. Outline • • • • • • Overview of USFDA Framework Biological Products How are Biologics different? Therapeutic Biologicals - Examples Biologics in CBER or CDER Regulation for Drugs & Biologics – – – – – – Comparison to drugs Inspection Team Overview & Review Process NDA and BLA (Similarities and Differences) NDA/BLA Dossier content BLA Post-approval requirement
  • 3. Overview of Regulatory Framework - USFDA Introduction: • The FDA is part of the Health and Human services Department of the US Government. • The FDA’s authority is based upon various laws and statutory documents. • The Food and Drug Administration (FDA) has responsibility for regulation of drugs and Biological products which are manufactured and / or sold in the US.
  • 4. Organizational Structure The FDA divided into following main Divisions or Centers.  Center for Drug Evaluation and Research (CDER)  Center for Biological Evaluation and Research (CBER)  Center for Devices and Radiological Health (CDRH)  Center for Veterinary Medicine (CVM)  Office of Regulatory Affairs (ORA)  Center for Food Safety and Applied Nutrition (CFSAN)  National Center for Toxicological Research (NCTR)  Center for Tobacco Products (CTP)
  • 6. Center for Drug Evaluation and Research (CDER) The CDER is responsible for the regulation of Chemically – derived and most therapeutic Biological products, both New Drugs and Generics.
  • 7. Center for Biologics Evaluation and Research (CBER) The Mission of CBER is to protect and enhance public health through the regulation of certain therapeutic Biological Products as well as Blood Products, Vaccines, Tissue and Gene Therapy Products.
  • 8. Center for Devices and Radiological Health (CDRH) The CDRH regulation of is responsible Medical for Devices Radiation Emitting products the and
  • 9. Center for Veterinary Medicine (CVM) The CVM regulation is of responsible Animal Medicinal Products or for the Veterinary
  • 10. Office of Regulatory Affairs (ORA) The ORA is the lead office for all field activities of the FDA. The duties and functions of ORA are divided between four main offices: • Resource Management • Regional Operation • Criminal Investigations • Enforcement. ORA regions are the Pacific, Southwest, Central, Southeast and Northeast regions of the US. Each region supports a number of local FDA offices.
  • 11. Office of Combination Products (OCP) The OCP is responsible for general oversight of the agency’s regulation of combination products. The primary responsibilities for regulating specific combination products remain in one of the product centers – CDER, CBER, CDRH. The OCP also oversees multi center reviews of combination products, ensures consistent and appropriate post-approval regulation of combination products, and resolves disputes relating to combination products.
  • 12. Biological Product (Biologic / Biologics / Biological) Biological Product – a “Virus, Therapeutic Serum, Toxin, Antitoxin, Vaccine, Blood, Blood Component or Derivative, Allergenic product, or Analogous product, applicable to the Prevention, Treatment or Cure of a Disease or Condition of human beings.” - As per Section 351 PHS Act
  • 13. Biologics vs. Drugs Biologic products generally more complex • Many innovative products. – Virtually every new biologic is a novel product (NME) • Demonstration of product comparability is more difficult. • Changes in manufacturing and scale-up can impede (obstruct) overall approval process.
  • 16. Biologics - Unique Aspects ! Source material for biologics – Potential for transmission of adventitious agents – Bacteria, mycoplasma, fungi, viruses, TSE agents – Need for in-process controls, validation process validation Heat Sensitive & susceptible to microbial contamination – Controlled temperature during production – Aseptic processing throughout – Cannot terminally sterilize Formulations – Majority Parenteral – Issues with concentration, Multi-use vials
  • 17. Pharmacokinetics – Not well established – May not be able to measure Potential Immunogenicity – Desirable in vaccine strategies – Unwanted effects in other settings (single or chronic-dosing) • Altered PK • Allergic, serum-sickness reactions • Cross reactivity to normal, essential protein – Limitations of non-clinical studies • Species-specific antibody development
  • 18. Therapeutic Biologicals Examples • Cytokines – Interferons- α, β, γ – Interleukins- IL2, IL11 • Hematopoietic growth factors – Erythropoietins – CSFs (Colony-stimulating factor) • Enzymes – Thrombolytics (e.g. streptokinase, TPA) – Aldurazyme
  • 19. Monoclonal Antibodies and related products – Anti-EGFR (Cetuximab, Panitumumab) – Anti-Alpha4 integrin (Natalizumab) Fusion proteins – TNFR linked to Fc portion of human IgG (Etanercept) Fab Fragments – Anti-VEGF (Ranibizumab) – Anti-TNFα (certolizumab pegol)
  • 20. Oncology – Herceptin (trastuzumab) breast cancer, ushers in new area of highly targeted therapy – Rituxan (rituximab) targets some lymphomas – Zevalin (ibritumomab tiuxetan), monoclonal antibody targeted radiotherapy – Campath (alemtuzumab) for CML (Chronic Myeloid Leukaemia) – Avastin (Bavacuzimab Bavacuzimab) first line metastatic colorectal Cancer
  • 21. CBER or CDER An applicant must determine which division of the FDA to submit its application, as the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) share responsibility for BLAs.
  • 22. Products Regulates by CBER • Allergenics Patch tests used to diagnose the causes of contact dermatitis. Extracts used to diagnose and treat rhinitis ("hay fever"), allergic sinusitis and conjunctivitis, and bee stings. • Blood Blood and blood components used for transfusion, such as red blood cells, plasma, and platelets.e.g Immunoglobuilns. • Devices Medical devices and tests used to safeguard blood, blood components, and cellular products from HIV, hepatitis, syphilis, and other infectious agents. Machines and related software used to collect blood and blood components. • Gene Therapy Gene therapy products that replace a person's faulty or missing genetic material. • Human Tissues and Cellular Products Human tissues for transplantation, such as skin, tendons, ligaments, and cartilage. Cellular products, such as human stem cells and pancreatic islets. • Vaccines Vaccines used for the prevention of infectious diseases, such as mumps, measles, chicken pox, diphtheria, tetanus, influenza, hepatitis, smallpox, and anthrax. • Xenotransplantation Products Xenotransplantation products use nonhuman tissues or organs into human recipients to treat human diseases such as liver failure, where human materials are not always available.
  • 23. Products Regulates by CDER Therapeutic Biological Products Transferred to CDER • Monoclonal antibodies for in vivo use. • Proteins intended for therapeutic use, including cytokines (e.g. interferons), enzymes (e.g. thrombolytics), and other novel proteins, This category includes therapeutic proteins derived from plants, animals, or microorganisms, and recombinant versions of these products. • Immunomodulators (non-vaccine and non-allergenic products intended to treat disease by inhibiting or modifying a pre-existing immune response). • Growth factors, cytokines, and monoclonal antibodies intended to mobilize, stimulate, decrease or otherwise alter the production of hematopoietic cells in vivo.
  • 24. About Combination Products Combination products are therapeutic and diagnostic products that combine drugs, devices, and/or biological products. Combination products involve components that would normally be regulated under different types of regulatory authorities, and frequently by different FDA Centers like CBER, CDER & CDRH. (i.e.,Drug/Device, Biologic/Device, Drug/Biologic, or Drug/Device/Biologic) Examples: – Orthopedic implant with growth factors, – Prefilled syringes – Metered dose inhalers – Transdermal patches – Catheter with antimicrobial coating
  • 25. Regulation for Drugs & Biologics
  • 26. Product Type FD & C Act PHS Act Component Jurisdiction Generic Equivalence Establishment Standards 21 CFR Part 211 21 CFR Part 312 21 CFR 600 21 CFR 314 Drugs Biological Products Products √ √ √ √ √ √ √ √ √ √ √ √ √
  • 27. Law or Act. Drug Products fall under the Food, Drug and Cosmetic Act. While Biological Products fall under the Food, Drug and Cosmetic act, & Public Health Service Act.
  • 28. Generic Equivalence Generics : Abbreviated New Drug Application (ANDA) A generic drug product is one that is comparable to an innovator drug product in Dosage form, Strength, Route of administration, Quality, Performance characteristics and Intended Use. While Follow-on Biologic or Biosimilar A follow-on biologic is similar but not identical to the brandname, or innovator, product made by the pharmaceutical or biotechnology industry; biosimilar is the term used in the European Union.
  • 29. Establishment Standards General Information – (i) Product, personnel, equipment, waste and air flow (ii) Illustration or indication of which areas are served by each air handling unit (iii) Air pressure differentials between adjacent areas. Water System – (i) General description of W/S (ii) Validation summary (iii) Routine w/s monitoring program. HVAC System – (Heating, Ventilation and Air Conditioning Systems), (i) General description (ii) Validation summary (iii) Routine monitoring program. Computer Systems – The application should contain information on computer systems which control critical manufacturing processes. Contamination/Cross Contamination Issues – The application should contain the following information regarding methods to prevent contamination and cross contamination to supplement information requested in the CMC (i) Cleaning procedures and validation (ii) Containment features.
  • 30. USFDA Pharmaceutical Team (Inspectorate) FDA’s Pharmaceutical Inspectorate was established under the agency’s Pharmaceutical cGMP’s for the 21st century: A Risk-Based Approach and Reporting to CDER
  • 31. USFDA Biologics Team The FDA team biologics was established in 1997 to assure the quality and safety of Biological Products. It consists of a core team of, 1. Certified ORA investigators, 2. CBER certified inspectors, and 3. Specially trained compliance officers representing both ORA and CBER
  • 34. NDA & BLA (Similarities and Differences)
  • 35. NDA and BLA - Similarities There are many similarities – Regulations – Guidance documents – PDUFA
  • 36. NDA and BLA - Similarities Specific Similarities Include • IND regulations, Fast Track designation, Special Protocol Assessment (SPA) • Financial Disclosure, CTD format • Labeling and Advertising (21CFR 201-202) • Pediatric study requirements and waivers • Accelerated Approval • Orphan Exclusivity
  • 37. Most differences are due to Type of Product Not due to which FDA Center Regulates The Product
  • 38. Unique to NDAs • Patent Exclusivity (Generics, 505b2, & Orange Book) • Pediatric Exclusivity (written requests) • NDA Field Copies • Regulations more detailed (NDA content; Filing criteria etc.)
  • 39. Unique to BLAs U.S. License • Product and facility must meet “Product standards” prior to license issuance • Review includes – – – – • Application review Facility inspection (Pre-approval, review members participate) Method validation (complete) Compliance check Cooperative manufacturing arrangements permitted – Divided, Shared, Contract FDA “official” release (21 CFR 610.2) of each product lot (at discretion of FDA) Container & Pkg. Label Requirements Specific information will be required depending on the type of BLA (e.g., Blood, Vaccines).
  • 40. NDA & BLA Application NDA and BLA are applications to market a new product. NDAs are used by CDER (center for drugs) and BLAs are used by CBER (center for biologics) – The BLA requires close scrutiny of the and facilities, because of the greater products. manufacturing process variability of biological – The application will include complete reports on all studies including patient listings, analysis according to the original statistical analysis protocol (SAP) as well as any exploratory analysis.
  • 41. – Although there is no regulatory mechanism in the U.S. to approve a generic version of a product that is marketed under a BLA, it is possible that a generic version of a biotech product that has been approved under an NDA could be approved. – This confusing situation results because some biotech products are approved under NDAs while others are approved under BLAs. – Review and approval of an NDA or BLA are based on the demonstration of safety and efficacy assessed from detailed reports of the clinical trials; particularly randomized controlled studies. – Biological products are a subset of drugs; therefore both are regulated under provisions of the FDC Act. However, only biological products are licensed under section 351 of the PHS Act. (As previously noted, some therapeutic protein products are approved under section 505 of the FDC Act, not under the PHS Act.) – Among other things, safety and purity assessments must consider the storage and testing of cell substrates that are often used to manufacture biologics. A potency assay is required due to the complexity and heterogeneity of biologics.
  • 42. Law Regulation (21 CFR) IND FD & C Act 25, 50, 211, 312 BLA FD & C Act. & PHS Act. 25, 201-2, 207, 211, 600 NDA FD & C Act. 25, 201-2, 207, 211, 314 Post BLA FD & C Act. & PHS Act. 201-2, 211, 600 FD & C Act. PDUFA 25, 201-2, 207, 211, 314 POST NDA ________ Same Same Where, CFR – Code of Federal Regulations PDUFA – Prescription Drug User Fee Act. IND – Investigational New Drug Application BLA – Biologics License Applications NDA – New Drug Application PART 25 Environmental Impact Considerations PART 50 Protection of Human Subjects PART 201 Labeling PART 211 Current Good Manufacturing Practice for Finished Pharmaceuticals PART 312 Investigational New Drug Application PART 207 Registration of producers of Drugs and listing of Drugs in Commercial Distribution PART 600 Biological Products: General PART 314 Applications for FDA approval to market a New Drug
  • 43. 21 CFR PART 600 BIOLOGICAL PRODUCTS: GENERAL Licensed biological products regulated by the Center for Biologics Evaluation and Research (CBER) Examples of such submissions include: Biologics license applications (BLAs) and their amendments and supplements, adverse experience reports, biological product deviation reports, fatality reports, and other correspondence.
  • 44. 21 CFR Part 600 BIOLOGICAL PRODUCTS: GENERAL • Subpart A: Definitions • Subpart B: Establishment Standards – Personnel – Facility, equipment, animals – Retention samples – Biological Product Deviations • Subpart C: Establishment Inspections • Subpart D: Reporting of Adverse Events – Postmarketing reporting – Distribution reports
  • 45. 21 CFR Part 610 GENERAL BIOLOGICAL : PRODUCT STANDARDS • Release – 610.1– lot release (manufacturer) – 610.2– Samples for “Official” FDA testing and release • Testing – – – – – Potency General Safety Sterility Purity (including moisture) Mycoplasma • Dating Periods • Labeling
  • 46. 21 CFR PART 314 Applications for FDA approval to market a New Drug Scope of this part. (a) This part sets forth procedures and requirements for the submission to, and the review by, the Food and Drug Administration of applications and abbreviated applications to market a new drug under section 505 of the Federal Food, Drug, and Cosmetic Act, as well as amendments, supplements, and postmarketing reports to them. (b) This part does not apply to drug products subject to licensing by FDA under the Public Health Service Act (58 Stat. 632 as amended (42 U.S.C. 201et seq. ) and subchapter F of chapter I of title 21 of the Code of Federal Regulations. Ref: 50 FR 7493, Feb. 22, 1985, as amended at 57 FR 17981, Apr. 28, 1992; 64 FR 401, Jan. 5, 1999
  • 47. Current Laws Public Health Service Act (1944) – Section 351 - Licensure of biological establishments and products. FFD&C Act (1938, 1962) – Interprets that “biological products” are also “drugs” – The FFD&C Act. applies to a biological product, except no application required under section 505.
  • 48. PHS Act The Secretary shall approve a biologics license application: – On the basis of a demonstration that • Product is safe, pure and potent • The facility (ies) meet standards designed to assure that it continues to be safe, pure, and potent – If the applicant consents to the inspection of the facility(ies) – Each package of biological product must bear the U.S. license number
  • 49. Product Standards CFR Standards for Biologics include: (p) “Safety” means the relative freedom from harmful effect to persons affected, directly or indirectly, by a product when prudently administered, taking into consideration the character of the product in relation to the condition of the recipient at the time. (r) “Purity” means relative freedom from extraneous matter in the finished product, whether or not harmful to the recipient or deleterious to the product. Purity includes but is not limited to relative freedom from residual moisture or other volatile substances and pyrogenic substances. (s) “Potency” is interpreted to mean the specific ability or capacity of the product, as indicated by appropriate laboratory tests or by adequately controlled clinical data obtained through the administration of the product in the manner intended, to effect a given result. - 21 CFR 600.3 and Part 610
  • 50. ‘Approval Letter’ “This letter hereby issues Department of Health and Human Services U.S. License No. XXXX to ___________ in accordance with the provisions of Section 351(a) of the Public Health Service Act controlling the manufacture and sale of biological products. This license authorizes you to introduce or deliver for introduction into interstate commerce, those products for which your company has demonstrated compliance with establishment and product standards.”
  • 51. BLA / NDA Dossier Content • • • • • • • • A copy of the cover letter attached to the archival copy A completed application Form FDA 356h A copy of the summary A copy of the general index of the entire application A letters of reference or authorization, if appropriate Patent Information Manufacturer Information Product/Manufacturing Information (CMC) – – – – – – • • • Source material / raw material Manufacturing process and controls Formulation Facility information Contamination / cross-contamination information Environment assessment or categorical exclusion Pre-clinical Studies Clinical Studies Labeling
  • 52. Application Forms FDA 356h – Application to Market a New or Abbreviated new drug or biologic for Human Use FDA-3356 – Establishment Registration and listing for Human cells, Tissues, And Cellular and Tissue based products (HCT/Ps) FDA-3486 – Biological Product deviation report Vaers form – Vaccine Adverse Event Reporting System
  • 53. Patent Information An applicant must submit information on each patent that claims the drug or a method of using the drug that is the subject of the BLA and with respect to which a claim of patent infringement could reasonably be asserted. An applicant must submit basic information about each patent, including the following: (i) Patent number and the date on which the patent will expire; (ii) Type of patent; (iii) Name of patent owner; (iv) If the patent owner or applicant does not reside or have a place of business within the U.S., the name of the agent of the patent owner or applicant who resides or maintains a place of business within the U.S. authorized to receive notice of patent certification.
  • 54. Labeling Label should include: (i) The proper name of the product; (ii) The name, address and license number of the manufacturer; (iii) The US License number must appear on the product labeling. (iv) The expiration date; (v) The recommended individual dose, for multiple dose containers; (vi) The statement “Rx only” for prescription Biologicals; and (vii) Minimum potency of product expressed in terms of official standard of potency or, if potency is a factor and no U.S. standard of potency has been prescribed, the word “No U.S. standard of potency”
  • 55. Biologic License Application (BLA) Under the Public Health Services Act, the Federal Food and Drug Administration (FDA) has been given the authority, concurrent with its authority under the Food Drug and Cosmetic Act, to regulate biologics. The FDA regulates a wide range of biologics, including, but not limited to, vaccines, blood and blood by-products, certain monoclonal antibodies, tissue and cellular products. Within the FDA, the Center for Biologics, as well as the Center for Drug Evaluation and Research, can be responsible for the regulation of biologics.
  • 56. – Biologics are evaluated for market by the FDA through the filing of a Biologic License Application (BLA). – A BLA, although similar to a New Drug Application (NDA), has its own set of intricate requirements. – Applicant has to provided the information in an acceptable format, under the applicable regulations. However, applicants must be cognizant that unique and specific information will be required depending on the type of BLA (e.g., blood, vaccines).
  • 57. Archival and Review Copies of BLA Federal regulations require the submission of two copies of a BLA – Archival and Review. Archival Copy The archival copy is a complete copy of an application submission and must be bound in a BLUE cover jacket. The archival copy should include a cover letter to: (i) confirm any agreements or understandings between the FDA and the applicant; (ii) identify a contact person regarding the application; (iii) identify the reviewing division of the FDA and the HFD number; and (iv) convey any other important information about the application.
  • 58. Review Copy The review copy is divided into six technical sections (“review sections”) and should be submitted with each review section separately bound in a specific color: (i) Chemistry, Manufacturing and Controls (CMC) – RED; (ii) Nonclinical Pharmacology and Toxicology – YELLOW; (iii) Human Pharmacokinetics and Bioavailability – ORANGE; (iv) Microbiology (if required) – WHITE; (v) Clinical Data – LIGHT BROWN; (vi) Statistical – GREEN. eCTD format starting no later than two years after the publication of the final guidance in the Federal Register, and final guidance is likely to enforce in mid-to-late 2015
  • 59. BLA Post-Approval Requirements • Required Annual Reports: – Post Marketing Commitment (PMC) status (601.70) • Other required submissions: – Adverse Events (600.80) – Distribution summary (600.81) – Biologic Deviation Reports (600.14) – Advertising and Promotional Labeling • Periodic cGMP inspections
  • 60. Changes to be Reported (21CFR 601.12) Manufacturing Changes – Pre- Approval Supplements (PAS) – 30 day Supplements (CBE30) – Annual Reports - only if reportable changes Labeling Changes – Pre Approval Supplements – Changes Being Effected (CBE) Supplements – Annual Reports - only if reportable changes
  • 61. Thank You ------ O -----GIRISH A. SWAMI Asst. Manager – DRA & DQA Serum Institute of India Ltd.